文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

肥胖危重症患者拔管时使用去甲肾上腺素:一项多中心验证的队列研究

Norepinephrine use at extubation in critically ill patients with obesity: a cohort study with multicenter validation.
PubMed 文献 · Intensive Care Med · 2025-08-06
一句话结论在肥胖危重症患者中,拔管时使用去甲肾上腺素(中位剂量0.6 mg/h,相当于实际体重0.097 µg/kg/min)未显著增加7天内再插管率。

该研究先在3186例前瞻性收集数据中回顾性分析主队列,其中837例肥胖患者,25%拔管时使用去甲肾上腺素,中位绝对剂量0.6 mg/h,相当于实际体重0.097(0.04-0.17)µg/kg/min。拔管时使用去甲肾上腺素者再插管率16%,未使用者17%,差异无统计学意义(p=0.85)。在多中心随机对照试验的656例肥胖患者验证队列中结果相似:使用去甲肾上腺素者再插管率18%,未使用者15%(p=0.45)。2349例非肥胖患者中也观察到相似结果。作者结论为肥胖危重症患者拔管时使用去甲肾上腺素未显著增加再插管率。

要点

  • 肥胖危重症患者拔管时使用去甲肾上腺素者7天内再插管率16%,未使用者17%,差异无统计学意义(p=0.85)。
  • 验证队列656例肥胖患者中,拔管时使用去甲肾上腺素者再插管率18%,未使用者15%,差异无统计学意义(p=0.45)。
  • 拔管时去甲肾上腺素中位剂量为绝对剂量0.6 mg/h,相当于实际体重0.097(0.04-0.17)µg/kg/min。
  • 非肥胖患者(2349例)中也观察到相似结果。
  • 作者结论:肥胖危重症患者拔管时使用去甲肾上腺素未显著增加再插管率。

适用人群与场景

  • 主队列为前瞻性收集数据、回顾性分析,共3186例危重症患者,其中837例肥胖患者。
  • 验证队列为多中心随机对照试验数据,其中656例肥胖患者、2349例非肥胖患者。
  • 研究场景为危重症患者拔管时。

处置流程与药物剂量

  • 拔管时使用去甲肾上腺素者中位剂量为绝对剂量0.6 mg/h,相当于实际体重0.097(0.04-0.17)µg/kg/min。

研究设计与关键结果

  • 研究类型:主队列为前瞻性收集数据的回顾性分析,验证队列为多中心随机对照试验数据的事后验证。
  • 主队列837例肥胖患者中,213例(25%)拔管时使用去甲肾上腺素,再插管率16%;未使用者再插管率17%,差异无统计学意义(p=0.85)。
  • 验证队列656例肥胖患者中,拔管时使用去甲肾上腺素者再插管率18%,未使用者15%,差异无统计学意义(p=0.45)。
  • 2349例非肥胖患者中也观察到相似结果。
  • 主要终点为7天内再插管率。

证据类型、等级与局限

  • 证据类型:主队列为前瞻性收集数据的回顾性分析,验证队列为多中心随机对照试验数据的验证分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:肥胖危重症患者拔管时使用去甲肾上腺素未显著增加再插管率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to assess whether norepinephrine at the time of extubation increases reintubation rates in critically ill patients with obesity.

METHODS: The initial step was to analyze data that had been collected prospectively, using a retrospective approach-defined as the main cohort. Then, we validated our findings using data from a multicenter randomized-controlled trial (validation cohort). The primary objective was to compare reintubation within 7 days, between patients with norepinephrine and without norepinephrine at the time of extubation. The secondary objective was to assess norepinephrine doses at extubation, normalized to body weight.

RESULTS: Among the 3186 patients included in the main cohort, 837 had obesity. Among them, 213 (25%) were extubated with norepinephrine, with a median norepinephrine dose at extubation of 0.6 mg/h of absolute value which corresponds to 0.097 (0.04-0.17) µg/kg/min of real body weight. No significant difference in reintubation rates was observed between patients extubated with norepinephrine (16%) and those without (17%, p = 0.85). Among the 656 patients with obesity in the validation cohort, we observed similar results, with a reintubation rate of 18% in those extubated with norepinephrine and 15% in those without (p = 0.45). Similar results were observed in the 2349 patients without obesity.

INTERPRETATION: In critically ill patients with obesity, the use of norepinephrine at the time of extubation did not significantly increase the reintubation rates.

CLINICAL TRIAL REGISTRATION: NCT04014920 for the validation cohort.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. De Jong A, Capdevila M, Aarab Y, et al. Norepinephrine use at extubation in critically ill patients with obesity: a cohort study with multicenter validation. Intensive Care Med. 2025. PMID: 40768069. doi:10.1007/s00134-025-08066-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。